NCT03234452

Brief Summary

A randomized, double-blind, placebo-controlled, cross-over trial performed at one centre in Italy to explore the ability of a multistrain probiotic mixture, to modulate markers of inflammation and intestinal barrier function and gastrointestinal symptoms in healthy volunteers with self-reported anxiety.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 23, 2016

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 21, 2016

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 18, 2017

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 26, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 31, 2017

Completed
Last Updated

September 9, 2019

Status Verified

September 1, 2019

Enrollment Period

4 months

First QC Date

July 26, 2017

Last Update Submit

September 6, 2019

Conditions

Keywords

Lactoflorene plusBifidobacterium animalis subsp. lactis, BB-12®Lactobacillus acidophilus, LA-5®Lactobacillus paracasei subsp. paracasei, L. CASEI 431®Inflammationgut permeabilitydisbiosisprobioticIgAIL10

Outcome Measures

Primary Outcomes (1)

  • NK activity

    Verify that Natural Killer activities concentration is significantly higher in the experimental Group compared to the placebo group

    45 days

Secondary Outcomes (4)

  • IgA, IL8, TNF-Alpha, IL10

    45 days

  • Cortisol, alpha-amylase , chromogranin A

    45 days

  • microbiota composition investigation

    45 days

  • Gastrointestinal symptoms (abdominal pain, aerophagia, diarrhea, constipation, diarrhea/constipation alternation )

    45 days

Study Arms (2)

Lactoflorene plus

EXPERIMENTAL

10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day

Dietary Supplement: Lactoflorene plus

Placebo Lactoflorene plus

PLACEBO COMPARATOR

Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.

Dietary Supplement: Placebo Lactoflorene plus

Interventions

Lactoflorene plusDIETARY_SUPPLEMENT

2 vials with dosing cap (10 mL) a day per os

Lactoflorene plus
Placebo Lactoflorene plusDIETARY_SUPPLEMENT

2 vials with dosing cap (10 mL) a day per os

Placebo Lactoflorene plus

Eligibility Criteria

Age20 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Eligible subjects were healthy men and women, 20-35 years old, with a STAI scale, form Y, module 1 (state anxiety) score of ≥ 35 and ≥40, for men and women, respectively.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centro Ricerche Cliniche di Verona Srl,

Verona, (Vr), 37100, Italy

Location

Related Publications (1)

  • Soldi S, Tagliacarne SC, Valsecchi C, Perna S, Rondanelli M, Ziviani L, Milleri S, Annoni A, Castellazzi A. Effect of a multistrain probiotic (Lactoflorene(R) Plus) on inflammatory parameters and microbiota composition in subjects with stress-related symptoms. Neurobiol Stress. 2018 Nov 7;10:100138. doi: 10.1016/j.ynstr.2018.11.001. eCollection 2019 Feb.

MeSH Terms

Conditions

DysbiosisAbdominal PainConstipationDiarrheaInflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsSigns and Symptoms, Digestive

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
double-blind
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: randomized, double-blind, placebo-controlled, cross-over trial performed at one centre
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 26, 2017

First Posted

July 31, 2017

Study Start

March 23, 2016

Primary Completion

July 21, 2016

Study Completion

April 18, 2017

Last Updated

September 9, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations